Defibrotide in the prevention of recurrences in venous thrombosis: DEPRIVE. A randomised, multicentre, European, double blind, parallel group study, to assess the efficacy and tolerability of defibrotide versus placebo in the prevention of recurrences in venous thromboembolism.

Trial Profile

Defibrotide in the prevention of recurrences in venous thrombosis: DEPRIVE. A randomised, multicentre, European, double blind, parallel group study, to assess the efficacy and tolerability of defibrotide versus placebo in the prevention of recurrences in venous thromboembolism.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 May 2011

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms DEPRIVE
  • Most Recent Events

    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top